SGLT-2 Inhibitor - Revision history

Danbot: Add See Also section

2026-03-22T09:14:53Z

Add See Also section

← Older revision		Revision as of 09:14, 22 March 2026
Line 19:		Line 19:
	==Mechanism of Action==		==Mechanism of Action==
	*Inhibit sodium-glucose cotransporter 2, decreasing glucose reabsorption in the proximal tubule		*Inhibit sodium-glucose cotransporter 2, decreasing glucose reabsorption in the proximal tubule

			==See Also==
			*[[Diabetes medications]]
			*[[Diabetic ketoacidosis]]
			*[[Hyperglycemia]]

	==References==		==References==

Kfarzam: /* Serious */

2022-08-20T06:06:50Z

Serious

← Older revision		Revision as of 06:06, 20 August 2022
Line 9:		Line 9:
	===Serious===		===Serious===
	*Euglycemic [[DKA]]<ref>[https://www.fda.gov/Drugs/DrugSafety/ucm446845.htm FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood]</ref>		*Euglycemic [[DKA]]<ref>[https://www.fda.gov/Drugs/DrugSafety/ucm446845.htm FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood]</ref>
			*Fournier's gangrene (rare)

	===Common===		===Common===

Elcatracho: /* Common */

2021-03-08T03:10:33Z

Common

← Older revision		Revision as of 03:10, 8 March 2021
Line 12:		Line 12:
	===Common===		===Common===
	*[[UTI]]		*[[UTI]]
	*Genital candidiasis		*Genital [[candidiasis]]
	*Weight loss		*Weight loss
	*Dehydration/Orthostasis		*Dehydration/Orthostasis

ClaireLewis: /* References */

2019-09-23T22:22:36Z

References

← Older revision		Revision as of 22:22, 23 September 2019
Line 23:		Line 23:

	[[Category:Pharmacology]]		[[Category:Pharmacology]]
			[[Category:Endocrinology]]

Carpenj at 03:20, 18 April 2017

2017-04-18T03:20:54Z

← Older revision		Revision as of 03:20, 18 April 2017
Line 1:		Line 1:
	==Administration==		==Administration==
	*Type: Oral [[Diabetes medication]]		*Type: Oral [[Diabetes medication]]
	*Canagliflozin (Invokana), Dapagliflozin (Farxiga), ~~empagliflozin~~ (Jardiance) are FDA approved for use in type 2 diabetes		*Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance) are FDA approved for use in type 2 diabetes

	==Contraindications==		==Contraindications==

Carpenj: /* Administration */

2017-04-18T03:20:30Z

Administration

← Older revision		Revision as of 03:20, 18 April 2017
Line 1:		Line 1:
	==Administration==		==Administration==
	*Type: [[Diabetes medication]]		*Type: Oral [[Diabetes medication]]
	*Canagliflozin (Invokana), Dapagliflozin (Farxiga), empagliflozin (Jardiance) are FDA approved for use in type 2 diabetes		*Canagliflozin (Invokana), Dapagliflozin (Farxiga), empagliflozin (Jardiance) are FDA approved for use in type 2 diabetes

Carpenj: /* Serious */

2017-04-18T03:20:06Z

Serious

← Older revision		Revision as of 03:20, 18 April 2017
Line 8:		Line 8:
	==Adverse Reactions==		==Adverse Reactions==
	===Serious===		===Serious===
	*Euglycemic DKA<ref>[https://www.fda.gov/Drugs/DrugSafety/ucm446845.htm FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood]</ref>		*Euglycemic [[DKA]]<ref>[https://www.fda.gov/Drugs/DrugSafety/ucm446845.htm FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood]</ref>

	===Common===		===Common===

Carpenj: /* Common */

2017-04-18T03:19:49Z

Common

← Older revision		Revision as of 03:19, 18 April 2017
Line 11:		Line 11:

	===Common===		===Common===
	*UTI		*[[UTI]]
	*Genital candidiasis		*Genital candidiasis
	*Weight loss		*Weight loss

Carpenj: Created page with "==Administration== Type: Diabetes medication Canagliflozin (Invokana), Dapagliflozin (Farxiga), empagliflozin (Jardiance) are FDA approved for use in type 2 diabetes ==..."

2017-04-18T03:15:08Z

Created page with "==Administration== *Type: Diabetes medication *Canagliflozin (Invokana), Dapagliflozin (Farxiga), empagliflozin (Jardiance) are FDA approved for use in type 2 diabetes ==..."

New page

==Administration==
*Type: [[Diabetes medication]]
*Canagliflozin (Invokana), Dapagliflozin (Farxiga), empagliflozin (Jardiance) are FDA approved for use in type 2 diabetes

==Contraindications==
*Allergy to class/drug

==Adverse Reactions==
===Serious===
*Euglycemic DKA<ref>[https://www.fda.gov/Drugs/DrugSafety/ucm446845.htm FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood]</ref>

===Common===
*UTI
*Genital candidiasis
*Weight loss
*Dehydration/Orthostasis

==Mechanism of Action==
*Inhibit sodium-glucose cotransporter 2, decreasing glucose reabsorption in the proximal tubule

==References==
<references/>

[[Category:Pharmacology]]